ANDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ZILEUTON (zileuton) by PharmaIN is 5-lipoxygenase inhibitors [moa]. Approved for 5-lipoxygenase inhibitor [epc]. First approved in 2020.
Drug data last refreshed 1w ago
Mechanism of Action
5-Lipoxygenase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Started Jan 2014
2 enrolled
Chronic Myelogenous Leukemia
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
Started Dec 2003
140 enrolled
Lung Cancer
Company
Worked on ZILEUTON at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.